nutrition-health-gastroenterologists-2019-scientifictracks

2 / 8

allied
academies
Page 24
Journal of Nutrition and Human Health | Volume 3
May 23-24, 2019 | Vienna, Austria
Joint Event
2nd International Conference on Gastroenterology and Digestive Disorders
17th International Conference on Nutrition and Fitness
&
Coloscape – A new liquid biopsy based Colorectal Cancer detection assay
Michael J Powell
DiaCarta, Inc., USA
Colorectal cancer is a highly preventable disease as
early detection increases rates of patient survival
to near 100%. Herein will be reported the development
and validation of a novel liquid biopsy based multigene
mutation biomarker real-time qPCR assay for qualitative
detection of colorectal cancer associated biomarkers that
comprise tumor specific mutations in the following genes:
APC (Exon 15), KRAS (Exon 2), BRAF (Exon 15) and CTNNB1
(Exon 3) in patients circulating cell-free DNA which is called
ColoScapeTM. The assay allows the sensitive detection
of the presence or absence of mutations in the targeted
regions of the genes interrogated. The assay was evaluated
on prospectively collected whole-blood samples obtained
from FIT+ patients enrolled in the CRC screening program
of ASL NAPOLI 3 SUD, using colonoscopy as confirmation.
The assay’s sensitivity for advanced adenomas was
evaluated as well as its specificity and other clinical
performance criteria. Based on these results which will
be reported in this presentation ColoScapeTM is a highly
promising oncology molecular diagnostic tool and further
clinical studies are underway in order to validate its use
for the triage of FIT+ patients. The ColoScapeTM assay
demonstrates high sensitivity and specificity in detection
of colon cancer and advanced adenomas based on the set
of biomarkers involved in colorectal cancer genesis and
disease progression.
Speaker Biography
Michael J Powell is a highly recognized scientific and business leader
with more than 30 years experience in R&D, technology, business
and corporate development. He has held R&D Director positions
at IGEN, Inc., Microgenics, Inc., Boehringer Mannheim GmbH and
Roche. He was a pioneer and lead scientist and inventor of the
electrochemiluminescence (ECL) assay technology and also developed
catalytic antibodies at IGEN, Inc. which was acquired by Roche for $1.4B
in 2003. He has held several other R&D senior management positions
at Integrated Genetics Inc., Medisense and Celltech PLC, in the UK.
Medisense was acquired by Abbott in 1996 for $900M and Celltech was
acquired by UCB Pharma in 2004 for $1.9B. He has extensive expertise
in the fields of molecular diagnostic assay research and development,
qPCR and other nucleic acid amplification technologies, high sensitivity
detection of cancer biomarkers in body fluids so called ‘liquid biopsy’
for cancer diagnosis and therapy management and automated in-vitro
diagnostics instrumentation platforms. He is currently Chief Scientific
Officer at DiaCarta, Inc. a precision diagnostics company.
e:
Notes: